XML 16 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenues:        
Revenue under collaborative research and development arrangements $ 16,358,316 $ 1,889,988 $ 20,646,902 $ 3,686,845
Revenue under collaborative research and development arrangements with affiliated entity 176,879 499,720 410,209 636,720
Grants and miscellaneous revenue 2,797,647 3,814,083 8,037,880 9,990,381
Grants and miscellaneous revenue from affiliated entity 1,079,282 0 1,693,318 0
Total revenues 20,412,124 6,203,791 30,788,309 14,313,946
Operating expenses:        
Research and development 23,878,751 19,630,801 48,421,255 37,819,961
General and administrative 6,169,106 5,799,530 13,936,695 11,171,143
Gain on sale of assets 0 (1,000,000) 0 (1,000,000)
Total operating expenses 30,047,857 24,430,331 62,357,950 47,991,104
Loss from operations (9,635,733) (18,226,540) (31,569,641) (33,677,158)
Other income (expense):        
Interest and other income, net 300,021 341,131 640,362 674,201
Change in fair value of common stock warrants, net (312,500) (113,775) (196,023) (520,024)
Gain (loss) on investment in affiliated entity 169,096 (705,527) (1,439,721) 6,775,450
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (9,479,116) $ (18,704,711) $ (32,565,023) $ (26,747,531)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders - basic and diluted ($ per share) $ (0.13) $ (0.26) $ (0.44) $ (0.37)
Weighted average number of common shares outstanding used in per share calculations - basic and diluted (shares) 75,409,702 72,957,159 74,783,791 72,591,986